Announcements Trials
Browse Landscape

Status

Completed 52Recruiting 34Active not recruiting 19Unknown 15Not yet recruiting 13Terminated 11Withdrawn 3Suspended 2Enrolling by invitation 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Cancer Metastatic 1

Interventions

Afatinib 33-Iodobenzylguanidine 3niraparib 2lenvatinib 2ibrutinib 2gallium 68 PSMA-11 2abemaciclib 2Trastuzumab 2Sunitinib 2Ramucirumab 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Gefitinib 2Fluorouracil 2Capecitabine 2Amifampridine 2Abiraterone Acetate 2zenocutuzumab 1vorasidenib 1tucatinib 1trilaciclib 1trifluridine tipiracil drug combination 1tovorafenib 1talquetamab 1tafasitamab 1selpercatinib 1sacituzumab govitecan 1ripretinib 1pralsetinib 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × trifluridine tipiracil drug combination × Clear all
NCT02286492 2024-09-05

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Taiho Oncology, Inc.

Approved for marketing
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡